

November 10, 2000	etasserse Argentes
Dockets Management Branch (HFA-305)	У
Food and Drug Administration	
5630 Fishers Lane, Room 1061	- 3
Rockville. MD 20852	
	دسه لبا

RE: Docket No. 00N-1494 "Agency Information Collection Activities; Proposed Collection: Comment Request; Medical Devices; Classification/Reclassification; Restricted Device: Analyte Specific Reagents"

BD Biosciences appreciates the opportunity to comment on the Analyte Specific Reagent (ASR) regulation, originally promulgated November 23, 1998. While the ASR regulation has achieved an important public health goal in providing an opportunity for manufacturers to provide important reagents for home brew assays, our customers have encountered a number of difficulties working within the limitations of the existing regulation. Some of these deal specifically with the restrictions for the instructions for use, warnings and precautions, and product support.

Below please find our specific recommendations.

1. Instructions for Use

Current: The ASR regulation currently states that an ASR must be labeled in accordance with 21 CFR 809.10(e). This section does not allow for instructions for use for ASRs. In the Federal Register Notice, 21 Nov. 1997, page 62252; the supplemental information to the ASR regulation, the FDA indicated that the products were restricted to high complexity laboratories because ASRs in these labs would be handled by individuals whose training and experience are likely to assure the safe and effective use of these reagents. It has been our

00N-1494

c C 1

experience that not all lab personnel working in a high complexity laboratory have such knowledge of basic assay development.

Proposed: Medical device manufacturers shall provide basic laboratory instructions for use and warn against uses that are not appropriate for the particular ASR. This would not include instructions for data interpretation nor would it include claims for precision or accuracy.

Discussion: Manufacturers have basic information about specific reagent characteristics to assist labs in setting up their testing procedures and to alert labs of important pitfalls to avoid. This information is often obtained from customer complaints and subsequent investigations into the root cause of these problems, which could be of service to other customers. Under the current labeling regulations, we as manufacturers are not permitted to provide basic information with respect to proper use of the reagent in an assay.

Providing additional reagent specific information would help customers develop better assays and avoid making critical errors when generating laboratory data.

Most clinical labs are under tight financial restrictions; therefore, education of the laboratory technician may be one of the first items to get cut from the laboratory's budget. For this reason, providing information limited to reagent characteristics under different laboratory conditions would lend critical support to laboratory technicians and help assure that the best data possible is generated for interpretation by the healthcare professional.

Without any instructions for use or guidance on warnings and precautions, a greater incidence of more critical product problems may result in an increased risk to public health.

2. Warnings and Precautions

Current: "A statement of warnings or precautions for users as established in the regulations contained in 16 CFR part 1500 and any other warnings appropriate to the hazard presented by the product" is allowed in the current regulations.

Proposed: A guidance or written clarification as to the scope of appropriate warnings and precautions would be helpful.

¹ 21 CFR 809.10(e)(1)(v)

Discussion: It is often very difficult to provide adequate warnings and precautions in the absence of being able to offer specific instructions for use. We would like to assist FDA in developing a guidance as to the permissible scope of the warnings and precautions section and to acknowledge that this section may be in conflict with the restrictions of other labeling sections. Without any instructions for use, laboratorians are at liberty to use products in very diverse ways. In order to maintain the expected reagent characteristics, limited acceptable instructions for proper handling of the reagents are needed.

3. Product Support

We have a responsibility to ensure that our products work properly in the hands of our customers. We have found that many customers requiring technical support are performing analyses at an unsatisfactory level. We have considerable knowledge about our reagents that would greatly benefit our customers. We want to make sure that our customers know how to properly set up our instruments, prepare samples, and generate good quality data. BD Biosciences believes it is in the best interests of patient care to be able to respond fully to customer technical inquiries. Data interpretation and medical diagnosis, in conjunction with other clinical information, would remain a medical responsibility outside of this regulation.

We appreciate the opportunity to comment on the current ASR regulation. We also appreciate FDA's ongoing efforts to create a better, less burdensome regulatory environment that retains as its central theme the protection of public health.

Sincerely, Jo am f. Lonzales for

Nancy E. Isaac, J.D., M.P.H.

Vice President, Regulatory Affairs

BD Biosciences

*** USA Airbill Tracking B231 2871 7437	Recipient's Copy
is portion can be removed for Recipient's records. 11/10/2000 FedEx Tracking Number 823128717437	4a Express Package Service Packages up to 150 lbs. Delivery commitment may be later in some areas. FedEx Priority Overnight Next business morning Packages up to 150 lbs. Delivery commitment may be later in some areas. FedEx Standard Overnight Next business morning FedEx Standard Overnight Gelivery be select to cations
Jo-Ann F. Gonzales Phone 408 432-9475	FedEx 2Day* Second business day FedEx Express Saver* Third business day *FedEx Envelope/Letter Rate not available Minimum charge: One-pound rate
BD BIOSCIENCES	4b Express Freight Service Packages over 150 lbs. Delivery commitment may be later in some areas.
2350 QUME DR	FedEx 1Day Freight* Next business day *Cell for Confirmation:
Dept/Hoor/Suite/Reom	5 Packaging *Declared value limit \$500
N JOSE State CA ZIP 95131	FedEx Envelope/Letter* FedEx Pak* Other Pkg.
mal Billing Reference	Includes FedEx Box, FedEx Tube, and customer pkg. 6 Special Handling Include FedEx address in Section 3.
SATURDAY Delivery Available for FedEx Priority Overnight and FedEx 2Dey Overnight to sear 2De Codes SUNDAY Delivery Available for FedEx Priority Overnight to sear 2De Codes SUNDAY Delivery Available for FedEx Priority Overnight to sear 2De Codes Not an appearance of the Company of the Company of the Code of the Company of the Code of the	
(HFA-305)	Does this shipment contain dengerous goods?
Food and Drug Administration Yes Shipper's Declaration Shipper's	
5630 Fishers Lane, ROOM 1061	Dangerous Goods cannot be shipped in FedEx packaging. Cargo Aircraft Only Payment Bill to: Obtain Recip.
Mick location, print FedEx address. We cannot deliver to P.O. boxes or P.O. ZIP codes.	Enter FedEx Acct. No. or Credit Card No. below. Sender Recipient Third Party Credit Card Cash/Check 1 will be biled.
Dept/Roor/Suite/Room	
RECKVILLE State MD ZIP 20852	Total Packages Total Weight Total Charges
	†Our liability is limited to \$100 unless you declare a higher value. See the FedEx Service Guide for details.
0158796	8 Release Signature Sign to authorize delivery without obtaining signature. By signing you authorize us to deliver this shipment without obtaining a signature and agree to indemnify and hold us harmless from any resulting claims. Q TED Questions? Call 1:3800-Go-FedEx* (800-463-3339)
	Visit our Web site at www.fedex.com SRS 800*Rev. Usis 3/00*Part #1559125* @1994-2000 FedEx*PRINTED IN U.S.A.

HOA